JP7602469B2 - Ｎｒｆ２活性剤としてのヒドロキシピリドキシアゼピン - Google Patents

Ｎｒｆ２活性剤としてのヒドロキシピリドキシアゼピン Download PDF

Info

Publication number
JP7602469B2
JP7602469B2 JP2021547429A JP2021547429A JP7602469B2 JP 7602469 B2 JP7602469 B2 JP 7602469B2 JP 2021547429 A JP2021547429 A JP 2021547429A JP 2021547429 A JP2021547429 A JP 2021547429A JP 7602469 B2 JP7602469 B2 JP 7602469B2
Authority
JP
Japan
Prior art keywords
methyl
dimethyl
dihydropyrido
benzo
triazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021547429A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022520442A (ja
JPWO2020165776A5 (enExample
Inventor
マーク、エルバン
ミハル、パウエル、グロゴフスキ
マイケル、クリントン、ケッティング
ブライアン、グリフィン、ローホーン
ジェイ、エム．マシューズ
ジャクリン、レニー、パターソン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Intellectual Property Development Ltd
Original Assignee
GlaxoSmithKline Intellectual Property Development Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Intellectual Property Development Ltd filed Critical GlaxoSmithKline Intellectual Property Development Ltd
Publication of JP2022520442A publication Critical patent/JP2022520442A/ja
Publication of JPWO2020165776A5 publication Critical patent/JPWO2020165776A5/ja
Application granted granted Critical
Publication of JP7602469B2 publication Critical patent/JP7602469B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2021547429A 2019-02-15 2020-02-11 Ｎｒｆ２活性剤としてのヒドロキシピリドキシアゼピン Active JP7602469B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962806201P 2019-02-15 2019-02-15
US62/806,201 2019-02-15
US201962931877P 2019-11-07 2019-11-07
US62/931,877 2019-11-07
PCT/IB2020/051100 WO2020165776A1 (en) 2019-02-15 2020-02-11 Hydroxypyridoxazepines as nrf2 activators

Publications (3)

Publication Number Publication Date
JP2022520442A JP2022520442A (ja) 2022-03-30
JPWO2020165776A5 JPWO2020165776A5 (enExample) 2023-02-21
JP7602469B2 true JP7602469B2 (ja) 2024-12-18

Family

ID=69726636

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021547429A Active JP7602469B2 (ja) 2019-02-15 2020-02-11 Ｎｒｆ２活性剤としてのヒドロキシピリドキシアゼピン

Country Status (18)

Country Link
US (3) US11945826B2 (enExample)
EP (1) EP3924356A1 (enExample)
JP (1) JP7602469B2 (enExample)
KR (1) KR20210126676A (enExample)
CN (2) CN118206566A (enExample)
AU (1) AU2020222080C1 (enExample)
BR (1) BR112021016042A2 (enExample)
CA (1) CA3129955A1 (enExample)
CL (1) CL2021002110A1 (enExample)
CO (1) CO2021010930A2 (enExample)
IL (2) IL285438B2 (enExample)
MA (1) MA54939A (enExample)
MX (1) MX2021009659A (enExample)
MY (1) MY209603A (enExample)
PH (1) PH12021551873A1 (enExample)
SG (1) SG11202108257TA (enExample)
TW (2) TWI843806B (enExample)
WO (1) WO2020165776A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2974026T3 (es) 2018-08-20 2024-06-25 Janssen Pharmaceutica Nv Inhibidores de la interacción proteína-proteína entre KEAP1-Nrf2
AR118050A1 (es) 2019-02-15 2021-09-15 Bristol Myers Squibb Co Compuestos bicíclicos sustituidos como moduladores del receptor farnesoide x
MY209603A (en) * 2019-02-15 2025-07-24 Glaxosmithkline Ip Dev Ltd Hydroxypyridoxazepines as nrf2 activators
MX2021014680A (es) * 2019-05-31 2022-04-06 Ube Corp Derivado de benzotriazol.
PE20241779A1 (es) 2022-01-07 2024-09-03 Chugai Pharmaceutical Co Ltd Compuesto heterociclico que contiene nitrogeno que tiene un efecto de activacion del nrf2
EP4516792A1 (en) * 2022-04-28 2025-03-05 Kyoto Pharmaceutical Industries, Ltd. Benzothiophene compound
WO2023210741A1 (ja) 2022-04-28 2023-11-02 第一三共株式会社 ベンゾトリアゾール化合物
EP4580612A1 (en) * 2022-09-02 2025-07-09 Institut National de la Santé et de la Recherche Médicale Use of nrf2 activators for the treatment of cerebral small vessel disease
CN121152792A (zh) * 2023-06-19 2025-12-16 中外制药株式会社 具有Nrf2活化作用的含氮杂环化合物的晶体

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017503786A (ja) 2013-12-18 2017-02-02 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ Ｎｒｆ２レギュレーター
WO2018109646A1 (en) 2016-12-15 2018-06-21 Glaxosmithkline Intellectual Property Development Limited Nrf2 compounds
JP2018517731A (ja) 2015-06-15 2018-07-05 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ Ｎｒｆ２レギュレーター

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2670099A1 (en) * 2006-11-17 2008-05-29 Trustees Of Dartmouth College Synthesis and biological activities of new tricyclic-bis-enones (tbes)
AU2016280235A1 (en) * 2015-06-15 2017-12-14 Astex Therapeutics Limited Nrf2 regulators
KR20180018684A (ko) 2015-06-15 2018-02-21 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 Nrf2 조절제
CA2995325A1 (en) * 2015-08-12 2017-02-16 Mochida Pharmaceutical Co., Ltd. Isothiazole derivative
US10364256B2 (en) * 2015-10-06 2019-07-30 Glaxosmithkline Intellectual Property Development Limited Biaryl pyrazoles as NRF2 regulators
CN108779108A (zh) * 2016-12-06 2018-11-09 葛兰素史密斯克莱知识产权发展有限公司 3-(2,3-二氢-1h-茚-5-基)丙酸衍生物和它们作为nrf2调节剂的用途
EP3551621A1 (en) * 2016-12-12 2019-10-16 GlaxoSmithKline Intellectual Property Development Limited N-aryl pyrazoles as nrf2 regulators
US11078216B2 (en) * 2016-12-14 2021-08-03 Glaxosmithkline Intellectual Property Development Limited Bisaryl amides as NRF2 activators
MY209603A (en) * 2019-02-15 2025-07-24 Glaxosmithkline Ip Dev Ltd Hydroxypyridoxazepines as nrf2 activators

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017503786A (ja) 2013-12-18 2017-02-02 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ Ｎｒｆ２レギュレーター
JP2018517731A (ja) 2015-06-15 2018-07-05 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ Ｎｒｆ２レギュレーター
WO2018109646A1 (en) 2016-12-15 2018-06-21 Glaxosmithkline Intellectual Property Development Limited Nrf2 compounds

Also Published As

Publication number Publication date
US20250313573A1 (en) 2025-10-09
PH12021551873A1 (en) 2022-05-23
WO2020165776A1 (en) 2020-08-20
CL2021002110A1 (es) 2022-02-11
TWI880702B (zh) 2025-04-11
EP3924356A1 (en) 2021-12-22
MY209603A (en) 2025-07-24
IL313950A (en) 2024-08-01
US11945826B2 (en) 2024-04-02
CN118206566A (zh) 2024-06-18
TWI843806B (zh) 2024-06-01
CO2021010930A2 (es) 2021-09-09
TW202440593A (zh) 2024-10-16
US20220204526A1 (en) 2022-06-30
JP2022520442A (ja) 2022-03-30
CA3129955A1 (en) 2020-08-20
IL285438B2 (en) 2024-12-01
MX2021009659A (es) 2021-09-08
CN113474349B (zh) 2024-03-01
MA54939A (fr) 2021-12-22
US20240352034A1 (en) 2024-10-24
TW202045514A (zh) 2020-12-16
KR20210126676A (ko) 2021-10-20
AU2020222080B2 (en) 2022-05-19
AU2020222080A1 (en) 2021-09-02
BR112021016042A2 (pt) 2021-10-05
CN113474349A (zh) 2021-10-01
IL285438A (en) 2021-09-30
IL285438B1 (en) 2024-08-01
AU2020222080C1 (en) 2022-09-29
SG11202108257TA (en) 2021-08-30

Similar Documents

Publication Publication Date Title
JP7602469B2 (ja) Ｎｒｆ２活性剤としてのヒドロキシピリドキシアゼピン
US11459327B1 (en) Cycloalkyl and hetero-cycloalkyl inhibitors, preparation methods therefor, and use thereof
JP7110197B2 (ja) Ｎｒｆ２アクチベーター
JP2018517732A (ja) Ｎｒｆ２レギュレーター
CA3066942A1 (en) Diazabicyclic substituted imidazopyrimidines and their use for the treatment of breathing disorders
EP4050008A1 (en) Pyridazinone or pyridazine compound and derivative and pharmaceutical composition thereof
JP2018529744A (ja) Ｎｒｆ２レギュレーターとしてのアリールシクロヘキシルピラゾール
WO2018109649A1 (en) Ether linked triazoles as nrf2 regulators
EP3555068B1 (en) 3-oxo-1,4-diazepinyle compounds as nrf2 activators
JP2021532107A (ja) ジカチオン化合物及びその製造方法と使用
EP4255568A1 (en) Novel ripk1 kinase targeting protacs and methods of use thereof
EP3796906A1 (en) Indanes as nrf2 activators
JP2020500918A (ja) Ｎｒｆ２レギュレーターとしてのｎ−アリールピラゾール
RU2812931C2 (ru) Гидроксипиридоксазепины в качестве активаторов nrf2
JP6809781B2 (ja) プテリン誘導体又はその塩
JP2016216446A (ja) ピロリジン−２，５−ジオン誘導体の多形形態、医薬組成物、およびｉｄｏ１阻害薬としての使用方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230213

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230213

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240202

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240208

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240502

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240702

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240802

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241101

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241119

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241206

R150 Certificate of patent or registration of utility model

Ref document number: 7602469

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150